At ACR Convergence 2024, the ACR honored clinical and research fellows in programs from New York to California and points between.
Environmental Threats in Rheumatic Disease
Rheumatic diseases are intrinsically linked to environmental conditions. With a constantly changing environment, how can rheumatologists adapt to the challenges of global climate change, pollution and other environmental threats? The Environment + Genetics Tamiko Katsumoto, MD, a clinical associate professor in the Division of Immunology and Rheumatology at Stanford University, Palo Alto, Calif., emphasizes the…
Tackling the Rheumatology Workforce Shortage
WASHINGTON, D.C.—The workforce shortage in rheumatology is a looming crisis that demands immediate attention. The ACR’s 2015 Workforce Study projected that by 2030, the supply of adult rheumatologists would dwindle by 31%, in contrast to the increase in demand by close to 138%.1 The situation is even worse for pediatric rheumatology and in rural and…
The Management of Psoriatic Arthritis: A Review
WASHINGTON, D.C.—As of November 2024, there are 16 biologic disease-modifying anti-rheumatic drugs (bDMARDs) that are FDA approved for the treatment of psoriatic arthritis (PsA). Incredible news, right? But as my fellowship program director used to say, “There’s no free lunch.” This buffet of options is excellent for our patients, but poses challenges to the practicing…
Young Adults with Psoriatic Disease at Risk of Early Cardiovascular Disease
Background/Purpose Psoriasis and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated with traditional cardiovascular disease risk factors and subclinical atherosclerosis. In older adults, systemic inflammation from psoriasis and PsA accelerates atherosclerosis, and these conditions are independent risk factors for severe cardiovascular disease…
15,000 Patient-Years: Safety Data for Upadacitinib Treatment Across Multiple Rheumatic Conditions
Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.
A View from Abroad: The ACR Research Exchange Program
The most recent ACR/APLAR Research Exchange Program gave participants an opportunity to visit Singapore, learn from international research presentations and create connections with colleagues they may never otherwise have met.
My Rheumatology Research Workshop 2024 Experience
The 2024 Rheumatology Research Workshop facilitated educational and relationship-building experiences for early-career and established rheumatology professionals alike.
Bringing Lupus into the Light
With more than 350 research abstracts on systemic lupus erythematosus, lupus nephritis and related conditions accepted for presentation at ACR Convergence 2024, we’re happy to announce that Graciela S. Alarcón, MD, MPH, has accepted the monumental task of reviewing the abstracts and identifying those most likely to make a difference to clinical practice or lead…
2024 Research Updates in ANCA-Associated & IgA Vasculitis
Summaries of selected research abstracts on ANCA-associated vasculitis & IgA vasculitis from the International Vasculitis Workshop.
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 91
- Next Page »